Missings [General Sta­tis­tics]

posted by d_labes  – Berlin, Germany, 2015-09-30 12:52 (3129 d 11:30 ago) – Posting: # 15497
Views: 25,237

Dear Shuanghe!

❝ ... By FDA's code, all subject has to complete all 4 periods. so In practice, number of subjects having T data is always equal number of to subjects having R data.


❝ By the way, I asked FDA about possibility of modify the code to include subject with 2 R and 1 T and for "ilat", the mean difference between T and R, use the modified version:

ilat = lat1t - 0.5*(lat1r+lat2r) ,

❝ where lat1t could be replaced by lat2t depending on period of dropout. It should be easy to implement with IF/ELSE/THEN. Buy they confirmed 1 and a half years later that subjects should have data of all 4 periods and reject the suggestion.


What you describe is the part of the SAS code concerning (µT-µR)^2 of the linearized scABE criterion (ilat analysis). For the part dealing with intra-subject variability the Progesterone / warfarin guidance SAS code (dlat analysis) does not automatically drop subjects having missings under Test treatment.

What to do here? Retain subjects having 2R, but only 1T or 0T? Or also drop them as we have done in the R code in the post below?

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,655 registered users;
79 visitors (0 registered, 79 guests [including 3 identified bots]).
Forum time: 00:22 CEST (Europe/Vienna)

So far as I can remember,
there is not one word in the Gospels
in praise of intelligence.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5